Why hasn’t there been more progress in developing therapies for Alzheimer’s disease and related forms of dementia? One reason has been the lack of specific laboratory tests that can properly diagnose and characterize these diseases. In this interview, Dr. Qinwen Mao from the University of Utah describes how her research team is helping to bring new blood and cerebrospinal fluid biomarkers into clinical practice to step up the fight against these devastating diseases. 

Related Information: Webinar: Innovations in Diagnostics for Alzheimer’s Disease and Related Dementias (aruplab.com/AlzInnovations)